266 related articles for article (PubMed ID: 25612903)
1. The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy.
Hosseini M; Haji-Fatahaliha M; Jadidi-Niaragh F; Majidi J; Yousefi M
Artif Cells Nanomed Biotechnol; 2016 Jun; 44(4):1051-61. PubMed ID: 25612903
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle.
Zhang K; Geddie ML; Kohli N; Kornaga T; Kirpotin DB; Jiao Y; Rennard R; Drummond DC; Nielsen UB; Xu L; Lugovskoy AA
MAbs; 2015; 7(1):42-52. PubMed ID: 25484041
[TBL] [Abstract][Full Text] [Related]
3. Application of nanostructured drug delivery systems in immunotherapy of cancer: a review.
Asadi N; Davaran S; Panahi Y; Hasanzadeh A; Malakootikhah J; Fallah Moafi H; Akbarzadeh A
Artif Cells Nanomed Biotechnol; 2017 Feb; 45(1):18-23. PubMed ID: 27196810
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticles for tumor immunotherapy.
Zang X; Zhao X; Hu H; Qiao M; Deng Y; Chen D
Eur J Pharm Biopharm; 2017 Jun; 115():243-256. PubMed ID: 28323111
[TBL] [Abstract][Full Text] [Related]
5. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
6. Antibody-targeted nanoparticles for cancer therapy.
Fay F; Scott CJ
Immunotherapy; 2011 Mar; 3(3):381-94. PubMed ID: 21395380
[TBL] [Abstract][Full Text] [Related]
7. [Development of a Nano DDS for Cancer Immunotherapy Based on Llipid Nanoparticles].
Nakamura T
Yakugaku Zasshi; 2018; 138(12):1443-1449. PubMed ID: 30504656
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy.
Musetti S; Huang L
ACS Nano; 2018 Dec; 12(12):11740-11755. PubMed ID: 30508378
[TBL] [Abstract][Full Text] [Related]
9. New approaches to antibody therapy.
Weiner LM; Adams GP
Oncogene; 2000 Dec; 19(53):6144-51. PubMed ID: 11156528
[TBL] [Abstract][Full Text] [Related]
10. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery.
Lu RM; Chang YL; Chen MS; Wu HC
Biomaterials; 2011 Apr; 32(12):3265-74. PubMed ID: 21306768
[TBL] [Abstract][Full Text] [Related]
11. Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy.
Zhong Y; Meng F; Deng C; Zhong Z
Biomacromolecules; 2014 Jun; 15(6):1955-69. PubMed ID: 24798476
[TBL] [Abstract][Full Text] [Related]
12. Antibody-targeted nanoparticles for cancer treatment.
Carter T; Mulholland P; Chester K
Immunotherapy; 2016 Jul; 8(8):941-58. PubMed ID: 27381686
[TBL] [Abstract][Full Text] [Related]
13. Targeting myeloid cells using nanoparticles to improve cancer immunotherapy.
Amoozgar Z; Goldberg MS
Adv Drug Deliv Rev; 2015 Aug; 91():38-51. PubMed ID: 25280471
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens.
Kuroki M; Shibaguchi H; Imakiire T; Uno K; Shirota K; Higuchi T; Shitama T; Yamada H; Hirose Y; Nagata A; Kuroki M
Anticancer Res; 2003; 23(6a):4377-81. PubMed ID: 14666724
[TBL] [Abstract][Full Text] [Related]
15. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
16. Engineering nanoparticle strategies for effective cancer immunotherapy.
Yoon HY; Selvan ST; Yang Y; Kim MJ; Yi DK; Kwon IC; Kim K
Biomaterials; 2018 Sep; 178():597-607. PubMed ID: 29576282
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapies to improve tumor immunotherapy.
Begley J; Ribas A
Clin Cancer Res; 2008 Jul; 14(14):4385-91. PubMed ID: 18628452
[TBL] [Abstract][Full Text] [Related]
18. Polymeric nanoparticulates for cancer immunotherapy.
Li W; Feng SS; Guo Y
Nanomedicine (Lond); 2013 May; 8(5):679-82. PubMed ID: 23656262
[No Abstract] [Full Text] [Related]
19. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
